Adenoviral vectors designed for expression of TGF-β1 type II receptor, which is a competitive inhibitor of TGF-β1, were injected into hindlimb muscles of a mouse model of diabetic nephropathy [35]. Here, TGFB1 is linked to diabetic kidney disease.